

# Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update – ERRATUM

Paul W. O'Connor, Marcelo Kremenchutzky

doi:10.1017/cjn.2015.400

Can J Neurol Sci. 2017; 44: 467

doi:http://dx.doi.org/10.1017/cjn.2015.296, Published by Cambridge University Press, 27 October 2015.

“Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update” by O'Connor & Kremenchutzky published with an error in the second paragraph under the section subheading “*Update on efficacy and safety evidence with natalizumab in MS*”, stating that “The multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetazel-Based Chemotherapy (AFFIRM)...”

The corrected sentence should read:

“The multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Natalizumab in Patients with Relapsing Multiple Sclerosis (AFFIRM)...”

We sincerely apologize for this error.

## REFERENCE

1. O'Connor P, Kremenchutzky M. Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update. Can J Neurol Sci. 2015;42:372-80. (doi:http://dx.doi.org/10.1017/cjn.2015.296).